AGEN : Summary for Agenus Inc. - Yahoo Finance

U.S. Markets closed

Agenus Inc. (AGEN)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.85+0.02 (+0.39%)
At close: 4:00PM EST
People also watch
CTICARRYCRISARIAEXEL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.83
Open3.79
Bid3.74 x 2000
Ask3.91 x 300
Day's Range3.75 - 3.88
52 Week Range2.73 - 7.49
Volume1,259,462
Avg. Volume1,217,491
Market Cap376.02M
Beta3.16
PE Ratio (TTM)-2.85
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Trials Of Agenus Inc (AGEN) Cancer Vaccine Ends In Absolute Failure
    Insider Monkey2 days ago

    Trials Of Agenus Inc (AGEN) Cancer Vaccine Ends In Absolute Failure

    Agenus Inc (NASDAQ:AGEN) has revealed that trials for a brain tumor vaccine have been halted after a lack of positive results. The announcement was contained in a federal filing that was made on Tuesday evening. No additional details were offered and neither was a press release issued by the Lexington-based company besides the report to […]

  • Troubling Trial Data Weighed on Agenus Inc Stock Today
    Motley Fool2 days ago

    Troubling Trial Data Weighed on Agenus Inc Stock Today

    Here's why Agenus shares are feeling some pressure today.

  • American City Business Journals3 days ago

    Lexington's Agenus quietly discloses failure of cancer vaccine trial

    Lexington cancer drug developer Agenus quietly disclosed late Tuesday that its most advanced vaccine for brain tumors had failed in a mid-stage study, sending shares of the company down slightly on Wednesday morning. Agenus (AGEN) revealed in a federal filing Tuesday night that a data and safety monitoring group had notified the company that the Phase 2 trial was likely futile. An interim analysis found that the survival rate of patients who received the company’s Prophage vaccine in combination with Genentech’s cancer drug Avastin would likely be no better than the survival rate of patients who only took Avastin.